Navigation Links
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Date:11/14/2013

SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC).  Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.

This acquisition will enable Sorrento to utilize the antibodies identified from its G-MAB® library along with Concortis' conjugation technologies and novel toxins to create a new generation of ADCs.  Concortis' proprietary C-lock™ and K-lock™ conjugation chemistries enable site-specific conjugation of toxins to the antibody, which will produce homogeneous ADCs with well-defined drug antibody ratios (DAR).  In contrast, approved ADCs are a heterogeneous mixture with different DARs.  This could potentially lead to better ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs and therefore, improved therapeutic efficacy and treatment safety.

"This is a transformational event for Sorrento as very few companies have the breadth of capabilities covering all facets of ADC technology, including the antibodies, the conjugation chemistries, and the toxins," said Henry Ji, Ph.D., President and CEO of Sorrento. "We are in an ideal position to become a leading player in this important and rapidly growing field. This also opens up new opportunities for strategic alliances."

As part of the transaction, upon the closing, David (Zhenwei) Miao, PhD, Co-Founder, President and CSO of Concortis will become Sorrento's Chief Technology Officer. Dr. Miao added, "The ADC space has become a fertile area for partnerships or acquisitions due to the recent FDA approvals of Adcetris®1 and Kadcyla®2. We are truly excited by the therapeutic promise of combining our proprietary ADC technologies with Sorrento's vast antibody pipeline."

About Sorrento G-MAB®  
The G-MAB® library is one of the industry's most diverse antibody library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>1016). Sorrento is advancing development of a number of potential drug product candidates, including antibodies against PD-L1, PD-1, VEGFR2, and chemokine receptors. The vast diversity of the G-MAB library has resulted in high success rate, even against difficult targets such as G Protein-Coupled Receptors (GPCRs).

About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer.  Sorrento's oncology pipeline includes Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in registrational studies under the abbreviated 505(b)(2) pathway. Sorrento is also developing Resiniferatoxin (RTX), the most potent TRPV1 agonist known, which is in a Phase 1/2 study at the National Institutes of Health (NIH) to treat terminal cancer patients suffering from intractable pain. Sorrento's proprietary G-MAB fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition to its proprietary ADCs, Sorrento is also developing Antibody formulated Drug Conjugates (AfDC) to target nanoparticles loaded with approved cancer drugs to tumors.

Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected.  Forward-looking statements include statements about the satisfaction of the closing conditions required to complete the merger with Concortis;  the potential for products to be successfully developed using the Concortis technologies; the synergies and prospects for a combined enterprise going forward, including the retention of key personnel; and the clinical development and commercial potential of conjugated antibodies that may be developed based on the acquired technologies; the potential for claims from third parties regarding the use of the antibody-drug conjugates and related technology that may be developed from the merger; the costs and expenses associated with the merger and additional clinical development programs from successful product development efforts; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2012, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings.  Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law. 

More information is available at www.sorrentotherapeutics.com.

1 Adcetris® is a registered trademark of Seattle Genetics.
2 Kadcyla® is a registered trademark of Roche Genentech.


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
8. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
9. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
10. Sorrento Therapeutics to Present at Two Healthcare Conferences
11. Sorrento Therapeutics Completes IgDraSol Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... With ... community have raised more than $15,000 in just a couple of weeks for ... grappling matches and world-class instructor seminars, organizers expect to double those initial funds ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected to receive ... Ross A. Clevens, MD, FACS . The founder and medical director of Clevens ... who trained at Yale, Harvard and the University of Michigan. He has served patients ...
(Date:9/19/2017)... York, NY (PRWEB) , ... September 19, 2017 ... ... firm, announced today the addition of strategic marketing leader, Denise Flannery, to its ... Strategic Marketing, Brand and Management Consultant, Denise will work with clients across different ...
(Date:9/19/2017)... ... 19, 2017 , ... PAPA Healthcare, Inc. announced today, the ... Healthcare helps fill gaps, provide essential insights, and improve productivity.” The story ... leveraging PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s Home Infusion ...
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 , ... ... has settled over 175,000 debt accounts, translating to in excess of $835 million in ... card debt and other unsecured loans are some of the categories of debt settled ...
Breaking Medicine News(10 mins):